Amgen Inc. DEF 14A: Executive Compensation Details
Ticker: AMGN · Form: DEF 14A · Filed: Apr 9, 2025 · CIK: 318154
| Field | Detail |
|---|---|
| Company | Amgen INC (AMGN) |
| Form Type | DEF 14A |
| Filed Date | Apr 9, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, sec-filing, equity-awards
Related Tickers: AMGN
TL;DR
Amgen's 2024 exec comp details are out - stock options & equity awards in focus.
AI Summary
Amgen Inc. filed its DEF 14A on April 9, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on stock options, equity awards, and changes in the fair value of outstanding awards for both principal executive officers (PEO) and non-PEO/non-executive officers.
Why It Matters
This filing provides transparency into how Amgen Inc. compensates its top executives, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not present immediate financial risks.
Key Numbers
- 2024 — Fiscal Year (Executive compensation data pertains to this year.)
- 2023 — Prior Fiscal Year (Comparative data for executive compensation.)
Key Players & Entities
- AMGEN INC (company) — Filer
- 0000318154 (company) — Central Index Key
- 20250409 (date) — Filing Date
- 20250523 (date) — Conformed Period of Report
- 2024-12-31 (date) — Fiscal Year End
FAQ
What is the total compensation for Amgen's Principal Executive Officer (PEO) for the fiscal year 2024?
The filing indicates data related to PEO members for the fiscal year 2024, but specific total compensation figures are not provided in this excerpt.
What types of equity awards are detailed in the filing?
The filing details changes in the fair value of outstanding and unvested equity awards granted in prior years, as well as year-end fair values of equity awards granted in covered years.
When was this DEF 14A filing submitted to the SEC?
The filing was submitted on April 9, 2025.
What is the fiscal year end for Amgen Inc.?
Amgen Inc.'s fiscal year ends on December 31.
Does the filing include compensation details for non-executive officers?
Yes, the filing includes data for non-PEO non-executive members regarding changes in the fair value of outstanding and unvested equity awards.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 9, 2025 regarding AMGEN INC (AMGN).